Caffeine Mouth Rinsing at Different Doses in Female Team-Sport Athletes: A Randomized, Double-Blind, Placebo-Controlled Trial

NCT07129863 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-08-19

No results posted yet for this study

Summary

Objective:

To evaluate the effects of different caffeine mouth rinse concentrations (1%, 2%, and 3%) on Running Anaerobic Sprint Test (RAST) performance in female team-sport athletes.

Main Questions:

1. Do caffeine mouth rinses improve RAST performance in female team-sport athletes?
2. Do different caffeine mouth rinse concentrations affect ratings of perceived exertion (RPE)?

Method:

Thirteen trained female football and handball players (23.0 ± 4.5 years) completed four randomized, double-blind, crossover conditions (1%, 2%, and 3% caffeine mouth rinses, and placebo). Each trial involved six 35 m sprints separated by 10 s of rest. RPE was recorded immediately after each session.

Conditions

  • Dietary Supplement
  • Sports Performance

Interventions

DIETARY_SUPPLEMENT

Placebo: Mouth rinse with plain water

Placebo: Mouth rinse with plain water, containing no caffeine, serving as the control condition.

DIETARY_SUPPLEMENT

Experimental: Low mouth rinse caffeine concentration (1%)

Arm Description: Low caffeine concentration: Mouth rinse containing 1% caffeine solution (based on weight/volume).

DIETARY_SUPPLEMENT

Moderate caffeine concentration (2% caffeine solution weight/volume).

Moderate caffeine concentration: Mouth rinse containing 2% caffeine solution (weight/volume).

DIETARY_SUPPLEMENT

High caffeine concentration (3% caffeine solution weight/volume).

High caffeine concentration: Mouth rinse containing 3% caffeine solution (weight/volume).

Sponsors & Collaborators

  • Eastern Mediterranean University

    collaborator OTHER
  • Northumbria University

    collaborator OTHER
  • Universidad Francisco de Vitoria

    collaborator OTHER
  • Ankara University

    collaborator OTHER
  • Universidad Pontificia Comillas

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-24
Primary Completion
2024-12-01
Completion
2024-12-22

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07129863 on ClinicalTrials.gov